已证明恶性疟原虫抗原SERP、HRPⅡ、MSA1及41-3都是具有保护效果的疫苗组分。1992年,作者应用大肠杆菌表达的杂合蛋白MS_2/SERP/HRPⅡ和SERP/MSA1/HRPⅡ接种夜猴的保护试验获得成功,这两个杂合蛋白均包括丝氨酸重复蛋白SERP的一个区(含2个T细胞表位)及富组氨酸蛋白HRPⅡ的C末端半部,MSA1为裂殖体表面抗原1的N末端区(含4个T细胞表位)。本文用3种杂合蛋白重复了猴体免疫试验。 Plasmodium falciparum antigens SERP, HRPII, MSA1 and 41-3 have all been shown to be vaccine components with protective effects. In 1992, the authors succeeded in the protection test of the monkey by inoculation of the hybrid proteins MS2 / SERP / HRPII and SERP / MSA1 / HRPII expressed in Escherichia coli. Both of these hybrid proteins include a serine repeat domain (2 T-cell epitopes) and the C-terminal half of histidine rich HRPII, MSA1 being the N-terminal region of Schizosaccharomyx antigen 1 (containing 4 T-cell epitopes). In this paper, monkeys immunized with three kinds of hybrid proteins were repeated.